Latest Pharma Insights
Execs On The Move: November 10–14, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 20, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 20, 2025
Jefferies 25: The Cardiometabolic Revolution Is Going Global
Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.
Scrip - November 20, 2025
Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.
Scrip - November 20, 2025
Novartis Signals Confidence In Mid-Term Sales As Trump Talks Shape Outlook
Novartis has projected 5%-6% sales growth through 2030 on the back of strong performances for some anticancers, even as MFN pricing and IRA negotiations loom.
Scrip - November 20, 2025
Novartis has projected 5%-6% sales growth through 2030 on the back of strong performances for some anticancers, even as MFN pricing and IRA negotiations loom.
Scrip - November 20, 2025
Executives On The Move: AstraZeneca China Gets New VP From Sanofi
Recent moves in the industry include new CEO hires at Alpha-9 Oncology, IAMA Therapeutics and Prokarium, plus QurAlis gets a new CMO from AbbVie.
Scrip - November 20, 2025
Recent moves in the industry include new CEO hires at Alpha-9 Oncology, IAMA Therapeutics and Prokarium, plus QurAlis gets a new CMO from AbbVie.
Scrip - November 20, 2025
Samsung Bioepis Pushes On With Pembrolizumab Phase III, Even As Others Terminate Trials
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Isturisa’s FDA Label Expansion Sets Up Blockbuster Potential For Recordati
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
Nanomi Steps Into The Spotlight As Lupin Launches US Long-Acting Risperidone
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
TEAM-NB Spells Out What Needs To Happen When Transferring Legacy Devices
The association’s recent position paper highlights how complex the transfer process is but explains to manufacturers and notified bodies how to meet the requirements.
Medtech Insight - November 20, 2025
The association’s recent position paper highlights how complex the transfer process is but explains to manufacturers and notified bodies how to meet the requirements.
Medtech Insight - November 20, 2025
Inside The Shift Toward Greener, Faster, Smarter Drug Manufacturing
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
Scrip - November 20, 2025
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
Scrip - November 20, 2025
Siemens’ 30% Healthineers Spin-Off Signals $23.2 Billion Unwind As Analysts Warn Of Pressure
CEO Bernd Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
CEO Bernd Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
Hemp’s Preclusion For Use As Dietary Ingredient In US Continues Even With THC Concerns Resolved
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Jefferies 25: The Cardiometabolic Revolution Is Going Global
Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.
Scrip - November 20, 2025
Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.
Scrip - November 20, 2025
Novartis Signals Confidence In Mid-Term Sales As Trump Talks Shape Outlook
Novartis has projected 5%-6% sales growth through 2030 on the back of strong performances for some anticancers, even as MFN pricing and IRA negotiations loom.
Scrip - November 20, 2025
Novartis has projected 5%-6% sales growth through 2030 on the back of strong performances for some anticancers, even as MFN pricing and IRA negotiations loom.
Scrip - November 20, 2025
Executives On The Move: AstraZeneca China Gets New VP From Sanofi
Recent moves in the industry include new CEO hires at Alpha-9 Oncology, IAMA Therapeutics and Prokarium, plus QurAlis gets a new CMO from AbbVie.
Scrip - November 20, 2025
Recent moves in the industry include new CEO hires at Alpha-9 Oncology, IAMA Therapeutics and Prokarium, plus QurAlis gets a new CMO from AbbVie.
Scrip - November 20, 2025
Inside The Shift Toward Greener, Faster, Smarter Drug Manufacturing
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
Scrip - November 20, 2025
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
Scrip - November 20, 2025
Execs On The Move: November 10–14, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 20, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 20, 2025
TEAM-NB Spells Out What Needs To Happen When Transferring Legacy Devices
The association’s recent position paper highlights how complex the transfer process is but explains to manufacturers and notified bodies how to meet the requirements.
Medtech Insight - November 20, 2025
The association’s recent position paper highlights how complex the transfer process is but explains to manufacturers and notified bodies how to meet the requirements.
Medtech Insight - November 20, 2025
Siemens’ 30% Healthineers Spin-Off Signals $23.2 Billion Unwind As Analysts Warn Of Pressure
CEO Bernd Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
CEO Bernd Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
Hemp’s Preclusion For Use As Dietary Ingredient In US Continues Even With THC Concerns Resolved
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Samsung Bioepis Pushes On With Pembrolizumab Phase III, Even As Others Terminate Trials
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Isturisa’s FDA Label Expansion Sets Up Blockbuster Potential For Recordati
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
Nanomi Steps Into The Spotlight As Lupin Launches US Long-Acting Risperidone
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
Deals In Depth: October 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
Podcast: Data-Driven Insights Reveal The Growth Engines Powering 2026 Life Sciences
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025